Elucidating the role of DEPTOR in Alzheimer's disease

Davies,Julie; Zachariades,Elena; Rogers-Broadway,Karly-Rai; Karteris,Emmanouil

doi:10.3892/ijmm.2014.1895

Elucidating the role of DEPTOR in Alzheimer's disease

Authors:
- Julie Davies
- Elena Zachariades
- Karly-Rai Rogers-Broadway
- Emmanouil Karteris
View Affiliations

Affiliations: Department of Biosciences, School of Health Sciences and Social Care, Brunel University, Uxbridge, UB8 3PH, UK
Published online on: August 12, 2014 https://doi.org/10.3892/ijmm.2014.1895
Pages: 1195-1200
Copyright: © Davies et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The mammalian or mechanistic target of rapamycin (mTOR) is a Ser/Thr protein kinase that, in response to nutrient stimulation, regulates cellular growth, proliferation, survival, protein synthesis and gene transcription. It has also been implicated in Alzheimer's disease (AD) with neuronal cells and hippocampal slices of AD transgenic mice experiencing dysregulated mTOR and synaptic plasticity in response to treatment with the toxic amyloid β (Aβ1-42) peptide, which has been implicated in AD. DEP domain-containing mTOR-interacting protein (DEPTOR) is a protein which can bind to mTOR and cause its inhibition, and functions as a regulatory protein of mTOR to control its activity. The inhibition of mTOR has been shown to have a neuroprotective effect; in an animal model, it was shown to protect against Aβ-induced neurotoxicity. In the present study, to investigate to role of DEPTOR in a model of AD, we neuronally differentiated the SH-SY5Y cell line and examined the effects of treatment with an Aβ42 peptide, thus mimicking plaque formation. This resulted in a significant increase in mTOR and a significant decrease in DEPTOR expression compared to the unstimulated controls. Moreover, to the best of our knowledge, we demonstrate for the first time a reduction in the protein level of DEPTOR in the precentral gyrus, postcentral gyrus and occipital lobe of a brain with AD compared to a normal control, as well as a significant reduction in DEPTOR expression in samples from late-onset AD (LOAD) compared to early-onset familial AD (EOFAD). The reduction in DEPTOR expression in cases of AD compared to healthy controls can lead to an augmentation of mTOR signalling, leading to Aβ accumulation, which in turn leads to a further reduction in DEPTOR expression. This results in the accumulation of amyloid plaque, shifting the balance from neuroprotection to neurodegeneration.

View Figures

View References

1	Pei JJ and Hugon J: mTOR-dependent signalling in Alzheimer’s disease. J Cell Mol Med. 12:2525–2532. 2008.PubMed/NCBI
2	Blennow K, de Leon MJ and Zetterberg H: Alzheimer’s disease. Lancet. 368:387–403. 2006.
3	Brown EJ, Albers MW, Shin TB, Ichikawa K, Keith CT, Lane WS, et al: A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature. 369:756–758. 1994. View Article : Google Scholar : PubMed/NCBI
4	Dennis PB, Jaeschke A, Saitoh M, Fowler B, Kozma SC and Thomas G: Mammalian TOR: a homeostatic ATP sensor. Science. 294:1102–1105. 2001. View Article : Google Scholar : PubMed/NCBI
5	Wullschleger S, Loewith R and Hall MN: TOR signaling in growth and metabolism. Cell. 124:471–484. 2006. View Article : Google Scholar : PubMed/NCBI
6	Hoeffer CA and Klann E: mTOR signaling: at the crossroads of plasticity, memory and disease. Trends Neurosci. 2:67–75. 2010. View Article : Google Scholar : PubMed/NCBI
7	Sutton MA and Schuman EM: Dendritic protein synthesis, synaptic plasticity, and memory. Cell. 127:49–58. 2006. View Article : Google Scholar : PubMed/NCBI
8	Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, et al: Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 460:392–395. 2009.PubMed/NCBI
9	Selman C, Tullet JM, Wieser D, Irvine E, Lingard SJ, Choudhury AI, et al: Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. Science. 326:140–144. 2009. View Article : Google Scholar : PubMed/NCBI
10	Boland B, Kumar A, Lee S, Platt FM, Wegiel J, Yu WH, et al: Autophagy induction and autophagosome clearance in neurons: relationship to autophagic pathology in Alzheimer’s disease. J Neurosci. 28:6926–6937. 2008.PubMed/NCBI
11	Lafay-Chebassier C, Paccalin M, Page G, Barc-Pain S, Perault-Pochat MC, Gil R, et al: mTOR/p70S6k signalling alteration by Abeta exposure as well as in APP-PS1 transgenic models and in patients with Alzheimer’s disease. J Neurochem. 94:215–225. 2005.PubMed/NCBI
12	Spilman P, Podlutskaya N, Hart MJ, Debnath J, Gorostiza O, Bredesen D, et al: Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer’s disease. PLoS One. 5:e99792010.PubMed/NCBI
13	Ma T, Hoeffer CA, Capetillo-Zarate E, Yu F, Wong H, Lin MT, et al: Dysregulation of the mTOR pathway mediates impairment of synaptic plasticity in a mouse model of Alzheimer’s disease. PLoS One. 5:e128452010.PubMed/NCBI
14	Peterson TR, Laplante M, Thoreen CC, Sancak Y, Kang SA, Kuehl WM, et al: DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell. 137:873–886. 2009. View Article : Google Scholar : PubMed/NCBI
15	Proud CG: Dynamic balancing: DEPTOR tips the scales. J Mol Cell Biol. 1:61–63. 2009. View Article : Google Scholar : PubMed/NCBI
16	Foster H, Coley HM, Goumenou A, Pados G, Harvey A and Karteris E: Differential expression of mTOR signalling components in drug resistance in ovarian cancer. Anticancer Res. 30:3529–3534. 2010.PubMed/NCBI
17	Liu M, Wilk SA, Wang A, Zhou L, Wang RH, Ogawa W, et al: Resveratrol inhibits mTOR signaling by promoting the interaction between mTOR and DEPTOR. J Biol Chem. 285:36387–36394. 2010. View Article : Google Scholar : PubMed/NCBI
18	Lopez-Miranda V, Soto-Montenegro ML, Vera G, Herradon E, Desco M and Abalo R: Resveratrol: a neuroprotective polyphenol in the Mediterranean diet. Rev Neurol. 54:349–356. 2012.PubMed/NCBI
19	Li Z, Pang L, Fang F, Zhang G, Zhang J, Xie M, et al: Resveratrol attenuates brain damage in a rat model of focal cerebral ischemia via up-regulation of hippocampal Bcl-2. Brain Res. 1450:116–124. 2012. View Article : Google Scholar : PubMed/NCBI
20	Huang TC, Lu KT, Wo YY, Wu YJ and Yang YL: Resveratrol protects rats from Abeta-induced neurotoxicity by the reduction of iNOS expression and lipid peroxidation. PLoS One. 6:e291022011. View Article : Google Scholar : PubMed/NCBI
21	Mparmpakas D, Zachariades E, Goumenou A, Gidron Y and Karteris E: Placental DEPTOR as a stress sensor during pregnancy. Clin Sci (Lond). 122:349–359. 2012. View Article : Google Scholar : PubMed/NCBI
22	Li X, An WL, Alafuzoff I, Soininen H, Winblad B and Pei JJ: Phosphorylated eukaryotic translation factor 4E is elevated in Alzheimer brain. Neuroreport. 15:2237–2240. 2004. View Article : Google Scholar : PubMed/NCBI
23	Steinerman JR, Irizarry M, Scarmeas N, Raju S, Brandt J, Albert M, et al: Distinct pools of beta-amyloid in Alzheimer disease-affected brain: a clinicopathologic study. Arch Neurol. 65:906–912. 2008. View Article : Google Scholar : PubMed/NCBI
24	Kuo YM, Emmerling MR, Vigo-Pelfrey C, Kasunic TC, Kirkpatrick JB, Murdoch GH, et al: Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem. 271:4077–4081. 1996. View Article : Google Scholar : PubMed/NCBI
25	Wang J, Dickson DW, Trojanowski JQ and Lee VM: The levels of soluble versus insoluble brain Abeta distinguish Alzheimer’s disease from normal and pathologic aging. Exp Neurol. 158:328–337. 1999.
26	Dwane S, Durack E and Kiely PA: Optimising parameters for the differentiation of SH-SY5Y cells to study cell adhesion and cell migration. BMC Res Notes. 6:3662013. View Article : Google Scholar : PubMed/NCBI
27	Petratos S, Li QX, George AJ, Hou X, Kerr ML, Unabia SE, et al: The beta-amyloid protein of Alzheimer’s disease increases neuronal CRMP-2 phosphorylation by a Rho-GTP mechanism. Brain. 131:90–108. 2008.
28	Bachmann RA, Kim JH, Wu AL, Park IH and Chen J: A nuclear transport signal in mammalian target of rapamycin is critical for its cytoplasmic signaling to S6 kinase 1. J Biol Chem. 281:7357–7363. 2006. View Article : Google Scholar : PubMed/NCBI
29	Sanchez-Espinosa MP, Atienza M and Cantero JL: Sleep deficits in mild cognitive impairment are associated with increased plasma amyloid-beta levels and cortical thinning. Neuroimage. 98:395–404. 2014. View Article : Google Scholar
30	Canu E, McLaren DG, Fitzgerald ME, Bendlin BB, Zoccatelli G, Alessandrini F, et al: Mapping the structural brain changes in Alzheimer’s disease: The independent contribution of two imaging modalities. J Alzheimers Dis. 26(Suppl 3): S263–S274. 2011.
31	Banno K, Nakaaki S, Sato J, Torii K, Narumoto J, Miyata J, et al: Neural basis of three dimensions of agitated behaviors in patients with Alzheimer disease. Neuropsychiatr Dis Treat. 10:339–348. 2014.PubMed/NCBI
32	Nagahama Y, Okina T, Suzuki N and Matsuda M: Neural correlates of psychotic symptoms in dementia with Lewy bodies. Brain. 133:557–567. 2010. View Article : Google Scholar : PubMed/NCBI
33	Bagyinszky E, Youn YC, An SS and Kim S: The genetics of Alzheimer’s disease. Clin Interv Aging. 9:535–551. 2014.
34	Borovecki F, Klepac N, Muck-Seler D, Hajnsek S, Mubrin Z and Pivac N: Unraveling the biological mechanisms in Alzheimer’s disease - lessons from genomics. Prog Neuropsychopharmacol Biol Psychiatry. 35:340–37. 2010.
35	Caccamo A, Maldonado MA, Majumder S, Medina DX, Holbein W, Magri A, et al: Naturally secreted amyloid-beta increases mammalian target of rapamycin (mTOR) activity via a PRAS40-mediated mechanism. J Biol Chem. 286:8924–8932. 2011. View Article : Google Scholar : PubMed/NCBI
36	Cai Z, Zhao B, Li K, Zhang L, Li C, Quazi SH, et al: Mammalian target of rapamycin: a valid therapeutic target through the autophagy pathway for Alzheimer’s disease? J Neurosci Res. 90:1105–1118. 2012.PubMed/NCBI